title: Abiraterone acetate withdrawal syndrome: does it exist?
abstract: In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy. We report the case of a patient who experienced a confirmed PSA decrease of ≤50% after stopping AA, mimicking an antiandrogen withdrawal syndrome.
authors.affiliation: Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Gauthier
authors.forename: Guilhem
authors.initials: G
authors.lastname: Bousquet
authors.forename: Damien
authors.initials: D
authors.lastname: Pouessel
authors.forename: Stéphane
authors.initials: S
authors.lastname: Culine
keywords: Abiraterone; Castrate-resistant prostate cancer; Prostate cancer; Withdrawal syndrome